AVITA Medical (ASX:AVH) reported preliminary unaudited results for the fourth quarter and full year of fiscal 2025, highlighting year-on-year revenue growth, a new US$60 million debt facility, and a positive revenue outlook for 2026.
The Valencia, California-based acute wound care company said fourth-quarter net revenues were approximately US$17.6 million, down from US$18.4 million a year earlier, while full-year 2025 revenues rose about 11% to US$71.6 million from US$64.3 million in 2024, within its revised guidance.
AVITA expects fiscal 2026 revenue to range between US$80 million and US$85 million, representing growth of roughly 12% to 19% compared with 2025.
The company also announced it had refinanced its existing debt through a new five-year credit facility with healthcare-focused investor Perceptive Advisors, securing up to US$60 million in committed capital.